Table 2 Survival analyses for specific comorbidities

Diabetes (n = 47)

1.20 (0.63–2.29)

0.93 (0.48–1.83)

Pulmonary hypertension (n = 20)

1.66 (0.75–3.68)

1.52 (0.67–3.43)

Lung cancer (n = 2)

3.19 (0.44–23.40)

2.32 (0.31–17.32)

Emphysema (n = 74)

1.04 (0.56–1.91)

1.24 (0.65–2.37)

Gastro-esophageal reflux disease (n = 46)

0.92 (0.46–1.83)

0.95 (0.46–1.96)

Arterial hypertension (n = 98)

1.25 (0.74–2.11)

1.02 (0.58–1.79)

Depression (n = 19)

1.75 (0.79–3.86)

1.75 (0.74–4.13)

Valve disease (n = 12)

1.18 (0.37–3.80)

0.85 (0.26–2.77)

Atrial fibrillation (n = 21)

1.66 (0.75–3.69)

0.90 (0.38–2.16)

Dyslipidemia (n = 31)

2.16 (1.18–3.96)

2.25 (1.19–4.24)

Coronary artery disease (n = 42)

1.35 (0.71–2.56)

1.06 (0.53–2.10)

Cancer (non-lung) (n = 16)

1.75 (0.69–4.40)

1.16 (0.44–3.06)

Osteoporosis (n = 21)

1.14 (0.49–2.65)

1.20 (0.50–2.87)

Cerebrovascular disease (n = 17)

1.85 (0.79–4.32)

1.64 (0.68–3.97)

Venous thromboembolism (n = 17)

0.80 (0.25–2.58)

0.48 (0.12–2.01)

Thyroid disease (n = 16)

0.64 (0.20–2.05)

0.74 (0.17–3.20)

Sleep apnea (n = 12)

*

*

Chronic heart failure (n = 9)

1.97 (0.84–4.61)

1.41 (0.58–3.42)

Chronic renal failure (n = 9)

0.83 (0.20–3.41)

0.58 (0.14–2.42)

Liver failure (n = 2)

*

*